e24139 Background: To evaluate the effects between oral sustained release opioids and other analgesic drugs on the quality of life, mood and dignity of patients with cancer pain. Methods: Participants were cancer patients with cancer pain recruited from a tertiary cancer hospital in North China. Patients were divided into group A (oral sustained-release strong opioids,) and group B (non-sustained release strong opioid analgesia, as tramadol, oxycodone aminophenol, non-steroidal analgesia, etc.) to assess their quality of life, mood and dignity. Data were collected using the Patient Dignity Inventory, the MD Anderson Symptom Inventory–Chinese, the distress thermometer, the Hospital Anxiety and Depression Scale, and the 30-question core Quality of Life Questionnaire from the European Organisation for Research and Treatment of Cancer, and were analyzed using quantitative methods. Results: The study included 297 cancer pain patients, including 172 males and 125 females, with a median age of 58 years, most of whom were lung cancer (n = 88), esophageal/gastric cancer (n = 63) and colorectal cancer (n = 52). Patients in group A(n = 224) had better pain control (P < 0.001), symptom burden (P < 0.001), psychological distress (P < 0.001), anxiety (P = 0.001) and Sense of dignity (P = 0.014) than those in group B(n = 73). In terms of quality of life assessment, patients in group A were more likely to suffer from nausea and vomiting (P = 0.003), and patients in group A were better than those in group B (Ps < 0.05), except for the similarity of social cognitive function, decreased appetite, diarrhea and constipation. Conclusions: The analgesic program with oral sustained - release strong opioids for cancer pain patients not only has better analgesic effect than other programs, but also has obvious advantages in physical symptoms, psychological emotion, sense of dignity and overall quality of life.